Form 4: Adaptive Biotechnologies Exec Sells Shares

Adaptive Biotechnologies Corp. CEO and Chairman Chad M. Robins has sold a significant number of company shares through a pre-arranged trading plan.

Summary

• Chad M. Robins, CEO and Chairman of Adaptive Biotechnologies Corporation, reported the sale of company stock on April 6, 2026, and April 8, 2026.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on August 11, 2025.
• On April 6, 2026, 83,332 shares were sold at a weighted average price of $14.41, with individual sales ranging from $14.19 to $14.84.
• On April 8, 2026, an additional 37,263 shares were sold at a weighted average price of $15.19, with individual sales ranging from $15.00 to $15.53.
• Following these transactions, Robins beneficially owns 2,180,518 shares of common stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative signal due to the significant volume of shares sold by the CEO, despite being executed under a pre-planned trading strategy.

Negatives

• Company insider, the CEO and Chairman, has sold a substantial number of shares.
• The total value of shares sold is approximately $1.7 million based on the reported weighted average prices.

Risks

• The sale of a large number of shares by a key executive could be interpreted negatively by the market, potentially impacting investor confidence.
• While executed under a 10b5-1 plan, significant insider selling can sometimes precede or coincide with negative company news, although no such news is presented here.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Management Comments

• The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.
• The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

Industry Context

StockSavvy.ai notes that insider selling, particularly by C-suite executives, is a common event. However, the scale of this sale, even under a 10b5-1 plan, warrants attention. Investors often scrutinize such transactions for insights into management's perception of the company's valuation and future prospects.

Stakeholder Impact

• Shareholders: May view the sale as a negative signal, potentially leading to short-term price pressure, despite the 10b5-1 plan.
• Employees: May experience reduced morale if the sale is perceived as a lack of confidence by leadership.
• Management: The CEO is diversifying his holdings, which is a standard personal financial management practice.

Next Steps

• Monitor future Form 4 filings for any additional insider transactions.
• Observe the market's reaction to this sale and Adaptive Biotechnologies' stock performance.

Key Dates

Recommendation

While the sale by the CEO is a point of concern, it was conducted under a pre-established 10b5-1 plan, mitigating concerns of opportunistic insider trading. The company's fundamental performance and future prospects, not detailed in this filing, would be the primary drivers for a buy or sell recommendation. Therefore, a 'hold' stance is appropriate pending further information.

Keywords

Adaptive Biotechnologies, ADPT, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Chad M Robins, CEO, Chairman